Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Huober J, Weder P, Ribi K, Thürlimann B, Thery J, Li Q, Vanlemmens L, Guiu S, Brain E, Grenier J, Dalenc F, Levy C, Savoye A, Müller A, Membrez-Antonioli V, Gerard M, Lemonnier J, Hawle H, Dietrich D, Boven E, Bonnefoi H, Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group. Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 2023
Aug 10, 2023
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Aug 10, 2023
JAMA Oncol 2023
Huober Jens, Weder Patrik, Ribi Karin, Thürlimann Beat, Thery Jean-Christophe, Li Qiyu, Vanlemmens Laurence, Guiu Séverine, Brain Etienne, Grenier Julien, Dalenc Florence, Levy Christelle, Savoye Aude-Marie, Müller Andreas S, Membrez-Antonioli Véronique, Gerard Marie-Aline, Lemonnier Jérôme, Hawle Hanne, Dietrich Daniel, Boven Epie, Bonnefoi Hervé R, Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group
more
